Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:11 AM
Ignite Modification Date:
2025-12-25 @ 1:11 AM
NCT ID:
NCT05257993
Brief Summary:
The purpose of this study is to assess the safety, tolerability of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer
Detailed Description:
In combination with JPI-547 and chemotherapy in patients with locally advanced/metastatic pancreatic cancer,
Primary Objectives
* To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D).
* To select the optimal combination chemotherapy based on the safety profile.
Secondary Objectives
* To assess the safety and toxicity.
* To evaluate anti-tumor activity.
Study:
NCT05257993
Study Brief:
Protocol Section:
NCT05257993